Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price

by Zagros on June 21, 2010

RICHMOND, Va. , June 21 /PRNewswire-FirstCall/ — Insmed Incorporated (NASDAQ CM: INSM), a biopharmaceutical company, today announced that on June 18, 2010 it received a NASDAQ Staff Deficiency Letter from The NASDAQ Stock Market.  The NASDAQ Letter states that for the last 30 consecutive business days, the closing bid price per share for the Company’s common stock has been below the $1.00 minimum per share requirement for continued inclusion under NASDAQ Marketplace Rule 5550(a)(2).

In accordance with NASDAQ Marketplace Rule 5810(c)(3)(A), Insmed will be provided 180 calendar days, or until December 15, 2010, to regain compliance by maintaining a closing bid price per share of $1.00 or higher for a minimum of 10 consecutive business days.  If the Company is unsuccessful in meeting the minimum bid requirement during this initial compliance period, Insmed will receive written notification from NASDAQ that its securities are subject to delisting, and at that time the Company may appeal the delisting determination to a Hearing’s Panel.  Alternatively, Insmed may be eligible for an additional grace period of 180 calendar days if the Company meets the initial listing standards, with the exception of bid price, for The NASDAQ Capital Market.  The NASDAQ Letter received on June 18, 2010 has no effect on the listing of the Company’s common stock at this time.  The Company will seek to regain compliance within this cure period and is considering appropriate business measures to address compliance with the continued listing standards of The NASDAQ Stock Market.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs.  For more information, please visit http://www.insmed.com.


Related Blogs

Leave a Comment

*

Previous post:

Next post:

Get Adobe Flash player